GcMAF
helps fight Autism and Cancer by rebuilding body's immune system.
Guernsey,
UK (February 8, 2013) -- On February 1, 2013, in simultaneous
presentations at the Immunology Conference in San Diego, California
and at the International Cancer Conference at the University of
Sharjah in the United Arab Emirates, Guernsey-based company, Immuno
Biotech Ltd. presented its latest research paper on GcMAF. The
presentation was entitled "Multifaceted immunotherapeutic
effects of GcMAF on human breast cancer cells."
It
included videos, taken through high powered microscopes in their
laboratory, showing cancer cells being destroyed using GcMAF
molecules, which they had extracted from human blood. GcMAF is a key
part of the human body's immune system and the body's own production
is often reduced as part of the attacking mechanism of diseases and
cancer.
Lynda
Thyer presented to an audience of over 200 American scientists at the
Immunology Conference and was congratulated on the content by other
scientists afterwards, in particular the videos which are a world
first.
David
Noakes, the CEO of Immuno Biotech, presented at the International
Cancer Conference and was told afterwards that his presentation was
the most easily understood in the three days of the conference. The
University was sufficiently impressed to ask Immuno Biotech to
provide GcMAF
for use with the University's huge library of 2,000 cancer cell
lines, so that GcMAF can be tested with many more types of cancers in
the laboratory. This will extend the knowledge of the effectiveness
of GcMAF which has mainly been used in human trials so far. The
University of Sharjah is one of the world leaders in cancer and
molecular research, with state-of-the-art facilities attracting
resident professors from all over the world.
David
Noakes will also be presenting Immuno Biotech's "GcMAF in
Autism" research paper at the International Dubai Autism
Conference, which was based on a US trial with 1500 autistic
children. Most of them had significant reductions in autistic
symptoms indicating that infection is playing a role in some forms of
autism. The company has already been asked to supply GcMAF for three
Dubai autism trials, on top of the 1,500 autistic children already
treated. The conference will be held from February 6-9, 2013 at Zayed
University, Dubai, bringing together international certified experts
in the fields of behavioural therapy and special education.
There
are 59 research papers by 142 eminent scientists on GcMAF, and Immuno
Biotech Ltd are immensely proud to be adding their first two research
papers to the list, with plans for lab experiments and human trial
results data for at least another six papers this year.
David
Noakes, Immuno Biotech's CEO, said, "Isolating GcMAF is a
complex process. Many scientists find it very challenging and time
consuming and often fail to isolate it correctly and so they come to
us as a source of consistent quality for their research. We have
perfected our process in a state-of-the-art laboratory in the UK that
isolates GcMAF from human blood and makes it available in a pure,
sterile form to scientists, doctors, patients and researchers around
the World. We are continually delighted by the flood of positive
results in scientific papers that state GcMAF helps fight an
increasingly wide range of diseases."
The
quality of Immuno Biotech's GcMAF has made it the World's leading
supplier and the provider of choice for scientists with the company
being cited in over eight research papers to date. Many of the
independent research papers on GcMAF are listed on its website
http://www.gcmaf.eu.
Background
GcMAF
is continually produced by healthy humans and is a vital part of the
body's immune system. It directs the immune system to destroy foreign
invaders, such as viruses and bacteria, as well as the body's own
cells when they turn cancerous. However, many diseases attempt to
prevent production of the body's own GcMAF and, if successful, that
prevents the immune system from fighting them resulting in the
diseases growing unchecked and becoming chronic.
Immuno
Biotech has perfected the technique of extracting and isolating GcMAF
molecules from healthy human blood. A weekly injection of a tiny
clear drop restores the level of GcMAF in the blood to normal and
enables the body's own natural defence mechanisms to fight the
infection with the only occasional side effects being mild, cold-like
symptoms as the immune system starts to function normally. Noticeable
improvements usually happen within three weeks and the time it takes
for the body to fight the infection and return to being able to
produce normal levels of its own GcMAF depends on the severity of the
infection or cancer. An eight week course costs €660 including
shipping so a typical 24 week course costs under €2000 - a fraction
of the cost of chemotherapy, and according to the research papers,
more effective at fighting
cancer. Immuno Biotech has supplied 4,000 patients
through 300 doctors in 30 nations.
Immuno
Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Tel:
0044 7781 411737, Web: http://gcmaf.eu
and click "contact" at the top to email.
